Johnson & Johnson (NYSE:JNJ) is set to report its Q3 2018 earnings on October 16, and we expect the company to post steady growth, led by a ramp up in its oncology drugs sales. J&J's key oncology drugs - Imbruvica, Darzalex, and Zytiga - have been on a strong run of late, and we expect this trend...
Johnson & Johnson (NYSE:JNJ) is set to report its Q3 2018 earnings on October 16, and we expect the company to post steady growth, led by a ramp up in its oncology drugs sales. J&J's key oncology drugs - Imbruvica, Darzalex, and Zytiga - have been on a strong run of late, and we expect this trend...
Share this Article
Recommended